MiNK Therapeutics (INKT) Begins Phase 2 Lung Injury Therapy Trial

AI Summary

MiNK Therapeutics (INKT) has initiated a Phase 2 clinical trial for its therapy aimed at treating lung injury. This development could have significant implications for the company's growth and market position, especially if results demonstrate efficacy. The trial's progress and outcomes will likely influence investor sentiment and trading volume in the biotechnology sector. No specific data points regarding funding or timeframe were reported in this announcement.